PHARMO Data

The PHARMO Institute has access to study-specific datasets derived from a network of electronic healthcare databases encompassing anonymous data from different primary and secondary healthcare settings in the Netherlands. These different data sources are linked on a patient level through validated algorithms. To ensure the privacy of the data, the collection, processing, linkage, and anonymization of the data is performed by STIZON. STIZON is an independent, ISO/IEC 27001 certified foundation, which acts as a Trusted Third Party (TTP) between the data sources and the PHARMO Institute. Our data offers tailor-made research cohorts for: post-authorization safety and efficacy (PASS, PAES) and drug utilization review (DUR); incidence/prevalence, treatment patterns, and patient pathways; comparative effectiveness, including synthetic control arms; healthcare resource use and cost of illness research; validation of surrogacy outcomes; as well as AI patient finding, classification, and disease progression prediction.

Disease areas that are addressable in the PHARMO Data Network with ease include slow-progressing illnesses, conditions managed across primary and secondary care settings, and rare diseases where ICD-10 codes are often underutilized.

More information about our data can be found here.